MUC1 and neoplasm: Some phase I/II clinical trials have proved that injecting DCs loaded with MUC1 peptide, mRNA or cDNA can effectively inhibit tumor growth, produce a long-lasting anti-tumor response and prolong survival [16,17]; this clearly indicates the potential and clinical application value of MUC1 as a tumor-associated antigen.